Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2003

View Archived Issues

Adenylate cyclase activators discovered at Nippon Kayaku

Merck designs new factor Xa and/or factor VIIa inhibitors

Novel anti-H. pylori agents that act by inhibiting MurI glutamate racemase

Lundbeck describes novel 5-HT1A ligands with 5-HT reuptake/dopamine receptor activity

GSK researchers discover new DPP inhibitors

Purine-based CDK inhibitors newly identified at Cyclacel

New PDE5 inhibitors in early development at Tanabe Seiyaku

Sunesis and Merck & Co. form Alzheimer's research collaboration

DakoCytomation obtains license for cancer diagnostic antibody

PhotoCure submits NDA for Metvix to FDA

Approvable letter issued for Zelapar

Eligard 30 mg receives FDA approval

Encouraging results obtained for Exanta in prevention of stroke in atrial fibrillation

Theseus Imaging enters clinical trial agreement with NCI for Hynic-Annexin V

U.S. centers cleared to join Pharmos's phase III trial of dexanabinol

Valentis updates progress of phase I del-1 trial

Phase III trial results announced for Riquent

HuMax-CD20 kills rituximab-resistant tumor cells in preclinical studies

New preclinical data reported for HuMax-EGFr

Canadian approval for Xigris

Potentially favorable pharmacokinetic and safety profile confirmed for UK-427857

A potential new target for HIV drugs: LEDGF/p75

Pyranodipyrimidine HIV integrase inhibitors with a novel mode of action

Atypical retinoid exerts potent antiproliferative and proapoptotic effects

Broadly crossreactive HIV-neutralizing antibodies available for licensing from NIH

Antidepressant- and anxiolytic-like effects for MCL-0129, a new MC4 receptor antagonist

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 11, 2025.
3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race
BioWorld
3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...
Corestemchemon preps US BLA filing for stem cell ALS therapy
BioWorld Asia
Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty
BioWorld
With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...